Kilitch Drugs (India) Limited (KILITCH.NS)
INR 333.7
(0.45%)
INR 333.7
(0.45%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.54 Billion INR | 10.58% |
| 2022 | 1.39 Billion INR | 22.2% |
| 2021 | 1.14 Billion INR | 66.71% |
| 2020 | 685.23 Million INR | 28.51% |
| 2019 | 533.2 Million INR | -35.36% |
| 2018 | 824.89 Million INR | 61.71% |
| 2017 | 510.11 Million INR | 78.04% |
| 2016 | 286.52 Million INR | 36.54% |
| 2015 | 209.85 Million INR | 10.29% |
| 2014 | 190.27 Million INR | 27.72% |
| 2013 | 148.98 Million INR | -55.1% |
| 2012 | 331.8 Million INR | -69.27% |
| 2011 | 1.07 Billion INR | -26.2% |
| 2010 | 1.46 Billion INR | 2.55% |
| 2009 | 1.42 Billion INR | 10.58% |
| 2008 | 1.29 Billion INR | 10.1% |
| 2007 | 1.17 Billion INR | 261.84% |
| 2006 | 323.83 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 334.51 Million INR | -25.36% |
| 2023 FY | 1.54 Billion INR | 10.58% |
| 2023 Q2 | 412.02 Million INR | 12.71% |
| 2023 Q1 | 365.57 Million INR | -19.61% |
| 2023 Q3 | 317.94 Million INR | -22.83% |
| 2023 Q4 | 448.18 Million INR | 40.96% |
| 2022 FY | 1.39 Billion INR | 22.2% |
| 2022 Q2 | 306.97 Million INR | -8.24% |
| 2022 Q3 | 299.72 Million INR | -2.36% |
| 2022 Q4 | 454.77 Million INR | 51.73% |
| 2022 Q1 | 334.52 Million INR | -8.62% |
| 2021 Q1 | 196.24 Million INR | -1.54% |
| 2021 Q2 | 235.7 Million INR | 20.11% |
| 2021 Q3 | 344.31 Million INR | 46.08% |
| 2021 Q4 | 366.07 Million INR | 6.32% |
| 2021 FY | 1.14 Billion INR | 66.71% |
| 2020 Q3 | 203.27 Million INR | 12.48% |
| 2020 FY | 685.23 Million INR | 28.51% |
| 2020 Q2 | 180.72 Million INR | 77.32% |
| 2020 Q1 | 101.91 Million INR | -12.32% |
| 2020 Q4 | 199.32 Million INR | -1.95% |
| 2019 Q3 | 159.29 Million INR | 3.88% |
| 2019 Q2 | 153.35 Million INR | 47.0% |
| 2019 Q1 | 104.31 Million INR | -45.57% |
| 2019 Q4 | 116.23 Million INR | -27.04% |
| 2019 FY | 533.2 Million INR | -35.36% |
| 2018 Q3 | 84.17 Million INR | -68.62% |
| 2018 FY | 824.89 Million INR | 61.71% |
| 2018 Q4 | 191.66 Million INR | 127.7% |
| 2018 Q2 | 268.2 Million INR | -4.5% |
| 2018 Q1 | 280.85 Million INR | 0.0% |
| 2017 FY | 510.11 Million INR | 78.04% |
| 2016 FY | 286.52 Million INR | 36.54% |
| 2015 FY | 209.85 Million INR | 10.29% |
| 2014 Q3 | 36.08 Million INR | -40.31% |
| 2014 Q2 | 60.44 Million INR | 8.71% |
| 2014 Q1 | 55.6 Million INR | -20.78% |
| 2014 Q4 | 38.14 Million INR | 5.71% |
| 2014 FY | 190.27 Million INR | 27.72% |
| 2013 Q3 | 13.11 Million INR | -54.47% |
| 2013 Q2 | 28.81 Million INR | -21.85% |
| 2013 Q1 | 36.86 Million INR | -48.71% |
| 2013 Q4 | 70.18 Million INR | 435.09% |
| 2013 FY | 148.98 Million INR | -55.1% |
| 2012 Q3 | 34.48 Million INR | -47.02% |
| 2012 Q2 | 65.09 Million INR | -57.82% |
| 2012 FY | 331.8 Million INR | -69.27% |
| 2012 Q1 | 154.31 Million INR | 0.0% |
| 2012 Q4 | 71.87 Million INR | 108.4% |
| 2011 FY | 1.07 Billion INR | -26.2% |
| 2010 FY | 1.46 Billion INR | 2.55% |
| 2009 FY | 1.42 Billion INR | 10.58% |
| 2008 FY | 1.29 Billion INR | 10.1% |
| 2007 FY | 1.17 Billion INR | 261.84% |
| 2006 FY | 323.83 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 97.474% |
| Hester Biosciences Limited | 3.04 Billion INR | 49.311% |
| Aarti Drugs Limited | 25.28 Billion INR | 93.895% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 91.497% |
| Albert David Limited | 3.62 Billion INR | 57.41% |
| Alembic Limited | 1.57 Billion INR | 1.977% |
| Alkem Laboratories Limited | 126.67 Billion INR | 98.781% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | -1.251% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 67.392% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -285.591% |
| Brooks Laboratories Limited | 794.86 Million INR | -94.213% |
| Eris Lifesciences Limited | 20.09 Billion INR | 92.317% |
| FDC Limited | 19.42 Billion INR | 92.055% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 93.239% |
| Gufic Biosciences Limited | 8.06 Billion INR | 80.863% |
| Hikal Limited | 17.84 Billion INR | 91.35% |
| Ind-Swift Limited | 5.02 Billion INR | 69.277% |
| Innova Captab Limited | 10.81 Billion INR | 85.724% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | 92.762% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | 26.032% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 97.697% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | 73.409% |
| Lupin Limited | 196.56 Billion INR | 99.215% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | 57.977% |
| Medico Remedies Limited | 1.44 Billion INR | -6.522% |
| Morepen Laboratories Limited | 17.01 Billion INR | 90.929% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 90.836% |
| Orchid Pharma Limited | 8.19 Billion INR | 81.16% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 86.591% |
| RPG Life Sciences Limited | 5.82 Billion INR | 73.478% |
| Sigachi Industries Limited | 3.98 Billion INR | 61.306% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 87.534% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 85.317% |
| Themis Medicare Limited | 3.81 Billion INR | 59.563% |
| Unichem Laboratories Limited | 16.57 Billion INR | 90.686% |
| Vaishali Pharma Limited | 862.79 Million INR | -78.921% |
| Wanbury Limited | 5.75 Billion INR | 73.183% |
| Windlas Biotech Limited | 6.3 Billion INR | 75.534% |
| ZIM Laboratories Limited | 3.67 Billion INR | 57.996% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 87.948% |
| Ipca Laboratories Limited | 77.05 Billion INR | 97.997% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.682% |
| Venus Remedies Limited | 5.91 Billion INR | 73.899% |
| Sakar Healthcare Limited | 1.54 Billion INR | -0.133% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 99.468% |
| Divi's Laboratories Limited | 78.45 Billion INR | 98.032% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 88.084% |
| Mankind Pharma Limited | 103.34 Billion INR | 98.506% |
| Sequent Scientific Limited | 13.69 Billion INR | 88.73% |
| Laurus Labs Limited | 50.01 Billion INR | 96.914% |
| Neuland Laboratories Limited | 15.58 Billion INR | 90.095% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | 95.522% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 98.693% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 99.188% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 63.352% |
| Wockhardt Limited | 27.89 Billion INR | 94.465% |
| Bal Pharma Limited | 3.39 Billion INR | 54.492% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.447% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 79.958% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -61.409% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | 90.794% |
| Shilpa Medicare Limited | 11.53 Billion INR | 86.612% |
| Valiant Laboratories Limited | 1.82 Billion INR | 15.207% |
| Ajanta Pharma Limited | 42.08 Billion INR | 96.332% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | 60.979% |
| Granules India Limited | 45.06 Billion INR | 96.574% |
| Medicamen Biotech Limited | 1.79 Billion INR | 13.906% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | 40.453% |
| Piramal Enterprises Limited | 60.33 Billion INR | 97.442% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 98.544% |
| NATCO Pharma Limited | 40.02 Billion INR | 96.143% |
| Suven Life Sciences Limited | 116.92 Million INR | -1220.224% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -206.164% |
| Strides Pharma Science Limited | 40.51 Billion INR | 96.189% |
| Indoco Remedies Limited | 18.17 Billion INR | 91.505% |
| Alpa Laboratories Limited | 1.08 Billion INR | -41.966% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -47.958% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -104.344% |